RE:Research Capital?Analysts are paid to have an opinion on stocks that their firm has financial ties with. Analysts have a bias and don't always point you to where the real treasure is.
IF the latest news turns out to be verified by further tests that Rutherin and Metformin combined prove to be a knock out punch to cancer. Then it's just a matter of time before this little Canadian biotech reaches a market cap of 3 to 10 Billion... depending on actual results.
Even a $2B market cap would mean a $8.26 stock without further dilution. Need to push this to the finish line and get some profit happening or else the vultures will be circling to pick up a cheap Patent.
Good luck to all the longs